help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Molecular Endocrinology, doi:10.1210/me.2002-0269
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marsaud, V.
Right arrow Articles by Renoir, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsaud, V.
Right arrow Articles by Renoir, J.-M.
Molecular Endocrinology 17 (10): 2013-2027
Copyright © 2003 by The Endocrine Society

Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor {alpha} (ER{alpha}), Differentially Affect ER{alpha} Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells

Véronique Marsaud, Angélique Gougelet, Sébastien Maillard and Jack-Michel Renoir

Pharmacologie Cellulaire et Moléculaire des Anticancéreux, Unité Mixte de Recherche 8612, Centre National de la Recherche Scientifique, 92296 Châtenay-Malabry, France

Address all correspondence and requests for reprints to: Jack-Michel Renoir, Pharmacologie Cellulaire et Moléculaire des Anticancéreux, Unité Mixte de Recherche 8612, Centre National de la Recherche Scientifique, 92296 Châtenay-Malabry, France. E-mail: Michel.Renoir{at}cep.u-psud.fr.

Estrogen receptor-{alpha} (ER) is down-regulated in the presence of its cognate ligand, estradiol (E2), as well as in the presence of antiestrogens, through the ubiquitin proteasome pathway. Here, we show that, at pharmacological concentrations, the degradation rate of pure antagonist/endogenous ER complexes from human breast cancer MCF-7 cells is 10 times faster than that of ER-E2 complexes, while 4-hydroxy-tamoxifen (4-OH-T)-ER complexes are stable. Whereas pure antagonist-ER complexes are firmly bound to a nuclear compartment from which they are not extractable, the 4-OH-T-ER accumulates in a soluble cell compartment. No difference was observed in the fate of ER whether bound to pure antiestrogens ICI 182,780 or RU 58668. Cycloheximide experiments showed that, while the proteasome-mediated destruction of E2-ER (unlike that of RU 58668- and ICI 182,780-ER) complexes could implicate (or not) a protein synthesis-dependent process, both MAPKs (p38 and ERKs p44 and p42) are activated. By using a panel of kinase inhibitors/activators to study the impact of phosphorylation pathways on ER degradation, we found that protein kinase C is an enhancer of proteasome-mediated degradation of both ligand-free and ER bound to either E2, 4-OH-T, and pure antagonists. On the contrary, protein kinase A, MAPKs, and phosphatidyl-inositol-3 kinase all impede proteasome-mediated destruction of ligand free and E2-bound ER while only MAPKs inhibit the degradation of pure antiestrogens/ER species. In addition, no correlation was found between the capacity of kinase inhibitors to affect ER stability and the basal or E2-induced transcription. These results suggest that, in MCF-7 breast cancer cells, ER turnover, localization, and activity are maintained by an equilibrium between various phosphorylation pathways, which are differently modulated by ER ligands and protein kinases.

NURSA Molecule Pages Link:

Nuclear Receptors:   ERα
Ligands:   17β-Estradiol



This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
G. Giamas, L. Castellano, Q. Feng, U. Knippschild, J. Jacob, R. S. Thomas, R. C. Coombes, C. L. Smith, L. R. Jiao, and J. Stebbing
CK1{delta} modulates the transcriptional activity of ER{alpha} via AIB1 in an estrogen-dependent manner and regulates ER{alpha}-AIB1 interactions
Nucleic Acids Res., May 1, 2009; 37(9): 3110 - 3123.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
N. B. Berry, M. Fan, and K. P. Nephew
Estrogen Receptor-{alpha} Hinge-Region Lysines 302 and 303 Regulate Receptor Degradation by the Proteasome
Mol. Endocrinol., July 1, 2008; 22(7): 1535 - 1551.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
C. Montani, M. Penza, M. Jeremic, G. Biasiotto, G. La Sala, M. De Felici, P. Ciana, A. Maggi, and D. Di Lorenzo
Genistein is an Efficient Estrogen in the Whole-Body throughout Mouse Development
Toxicol. Sci., May 1, 2008; 103(1): 57 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
N. Picard, C. Charbonneau, M. Sanchez, A. Licznar, M. Busson, G. Lazennec, and A. Tremblay
Phosphorylation of Activation Function-1 Regulates Proteasome-Dependent Nuclear Mobility and E6-Associated Protein Ubiquitin Ligase Recruitment to the Estrogen Receptor {beta}
Mol. Endocrinol., February 1, 2008; 22(2): 317 - 330.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
C. C Valley, N. M Solodin, G. L Powers, S. J Ellison, and E. T Alarid
Temporal variation in estrogen receptor-{alpha} protein turnover in the presence of estrogen
J. Mol. Endocrinol., January 1, 2008; 40(1): 23 - 34.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
D. Nonclercq, F. Journe, I. Laios, C. Chaboteaux, R.-A. Toillon, G. Leclercq, and G. Laurent
Effect of nuclear export inhibition on estrogen receptor regulation in breast cancer cells
J. Mol. Endocrinol., August 1, 2007; 39(2): 105 - 118.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, et al.
Estrogen Receptors: How Do They Signal and What Are Their Targets
Physiol Rev, July 1, 2007; 87(3): 905 - 931.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Duong, N. Boulle, S. Daujat, J. Chauvet, S. Bonnet, H. Neel, and V. Cavailles
Differential Regulation of Estrogen Receptor {alpha} Turnover and Transactivation by Mdm2 and Stress-Inducing Agents
Cancer Res., June 1, 2007; 67(11): 5513 - 5521.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Zheng, A. Kallio, and P. Harkonen
Tamoxifen-Induced Rapid Death of MCF-7 Breast Cancer Cells Is Mediated via Extracellularly Signal-Regulated Kinase Signaling and Can Be Abrogated by Estrogen
Endocrinology, June 1, 2007; 148(6): 2764 - 2777.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. J. Han, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley
Distinct Temporal and Spatial Activities of RU486 on Progesterone Receptor Function in Reproductive Organs of Ovariectomized Mice
Endocrinology, May 1, 2007; 148(5): 2471 - 2486.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Lupien, M. Jeyakumar, E. Hebert, K. Hilmi, D. Cotnoir-White, C. Loch, A. Auger, G. Dayan, G.-A. Pinard, J.-M. Wurtz, et al.
Raloxifene and ICI182,780 Increase Estrogen Receptor-{alpha} Association with a Nuclear Compartment via Overlapping Sets of Hydrophobic Amino Acids in Activation Function 2 Helix 12
Mol. Endocrinol., April 1, 2007; 21(4): 797 - 816.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. H. Al-Dhaheri and B. G. Rowan
Protein Kinase A Exhibits Selective Modulation of Estradiol-Dependent Transcription in Breast Cancer Cells that Is Associated with Decreased Ligand Binding, Altered Estrogen Receptor {alpha} Promoter Interaction, and Changes in Receptor Phosphorylation
Mol. Endocrinol., February 1, 2007; 21(2): 439 - 456.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N Sarwar, J-S Kim, J Jiang, D Peston, H D Sinnett, P Madden, J M Gee, R I Nicholson, A E Lykkesfeldt, S Shousha, et al.
Phosphorylation of ER{alpha} at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ER{alpha} phosphorylation in breast cancer progression.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 851 - 861.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
E. T. Alarid
Lives and Times of Nuclear Receptors
Mol. Endocrinol., September 1, 2006; 20(9): 1972 - 1981.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Long and K. P. Nephew
Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate Immobilization and Degradation of Estrogen Receptor-{alpha}
J. Biol. Chem., April 7, 2006; 281(14): 9607 - 9615.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. M Dougherty, W. Mazhawidza, A. R Bohn, K. A Robinson, K. A Mattingly, K. A Blankenship, M. O Huff, W. G McGregor, and C. M Klinge
Gender difference in the activity but not expression of estrogen receptors {alpha} and {beta} in human lung adenocarcinoma cells.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 113 - 134.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
E Horner-Glister, M Maleki-Dizaji, C J Guerin, S M Johnson, J Styles, and I N H White
Influence of oestradiol and tamoxifen on oestrogen receptors-{alpha} and -{beta} protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells
J. Mol. Endocrinol., December 1, 2005; 35(3): 421 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Fan, A. Park, and K. P. Nephew
CHIP (Carboxyl Terminus of Hsc70-Interacting Protein) Promotes Basal and Geldanamycin-Induced Degradation of Estrogen Receptor-{alpha}
Mol. Endocrinol., December 1, 2005; 19(12): 2901 - 2914.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Luo, M. Koh, J. Feng, Q. Wu, and P. Melamed
Cross Talk in Hormonally Regulated Gene Transcription through Induction of Estrogen Receptor Ubiquitylation
Mol. Cell. Biol., August 15, 2005; 25(16): 7386 - 7398.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. H. Gutzman, S. E. Nikolai, D. E. Rugowski, J. J. Watters, and L. A. Schuler
Prolactin and Estrogen Enhance the Activity of Activating Protein 1 in Breast Cancer Cells: Role of Extracellularly Regulated Kinase 1/2-Mediated Signals to c-fos
Mol. Endocrinol., July 1, 2005; 19(7): 1765 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Callige, I. Kieffer, and H. Richard-Foy
CSN5/Jab1 Is Involved in Ligand-Dependent Degradation of Estrogen Receptor {alpha} by the Proteasome
Mol. Cell. Biol., June 1, 2005; 25(11): 4349 - 4358.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. Cho, D. Kim, S. Lee, and Y. Lee
Cobalt Chloride-Induced Estrogen Receptor {alpha} Down-Regulation Involves Hypoxia-Inducible Factor-1{alpha} in MCF-7 Human Breast Cancer Cells
Mol. Endocrinol., May 1, 2005; 19(5): 1191 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Cui, M. Zhang, R. Pestell, E. M. Curran, W. V. Welshons, and S. A. W. Fuqua
Phosphorylation of Estrogen Receptor {alpha} Blocks Its Acetylation and Regulates Estrogen Sensitivity
Cancer Res., December 15, 2004; 64(24): 9199 - 9208.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. K. Vadlamudi, S. Balasenthil, R. R. Broaddus, J.-A. Gustafsson, and R. Kumar
Deregulation of Estrogen Receptor Coactivator Proline-, Glutamic Acid-, and Leucine-Rich Protein-1/Modulator of Nongenomic Activity of Estrogen Receptor in Human Endometrial Tumors
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6130 - 6138.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A.-M. Gaben, C. Saucier, M. Bedin, G. Redeuilh, and J. Mester
Mitogenic Activity of Estrogens in Human Breast Cancer Cells Does Not Rely on Direct Induction of Mitogen-Activated Protein Kinase/Extracellularly Regulated Kinase or Phosphatidylinositol 3-Kinase
Mol. Endocrinol., November 1, 2004; 18(11): 2700 - 2713.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Garofalo, D. Sisci, and E. Surmacz
Leptin Interferes with the Effects of the Antiestrogen ICI 182,780 in MCF-7 Breast Cancer Cells
Clin. Cancer Res., October 1, 2004; 10(19): 6466 - 6475.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. T. Gaddy, J. T. Barrett, J. N. Delk, A. M. Kallab, A. G. Porter, and P. V. Schoenlein
Mifepristone Induces Growth Arrest, Caspase Activation, and Apoptosis of Estrogen Receptor-Expressing, Antiestrogen-Resistant Breast Cancer Cells
Clin. Cancer Res., August 1, 2004; 10(15): 5215 - 5225.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H.-W. Tsai, J. A. Katzenellenbogen, B. S. Katzenellenbogen, and M. A. Shupnik
Protein Kinase A Activation of Estrogen Receptor {alpha} Transcription Does Not Require Proteasome Activity and Protects the Receptor from Ligand-Mediated Degradation
Endocrinology, June 1, 2004; 145(6): 2730 - 2738.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Barchiesi, E. K. Jackson, B. Imthurn, J. Fingerle, D. G. Gillespie, and R. K. Dubey
Differential Regulation of Estrogen Receptor Subtypes {alpha} and {beta} in Human Aortic Smooth Muscle Cells by Oligonucleotides and Estradiol
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2373 - 2381.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society